



The TIMI Trials

DISPERSE2-TIMI 33

OBJECTIVE: To evaluate the safety, tolerability, and efficacy of AZD6140, an oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome.

1. [Cannon CP](#), [Husted S](#), [Harrington RA](#), [Scirica BM](#), [Emanuelsson H](#), [Peters G](#), [Storey RF](#); [DISPERSE-2 Investigators](#). Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. *J Am Coll Cardiol* 2007;50:1844-51.
2. Cannon CP, Harrington RA, Mahaffey KW, Husted S, Storey RF, Sanders N, Peters G, Emanuelsson H. Clinical outcomes with AZD6140, an oral reversible ADP receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes (ACS). *J Am Coll Cardiol* 2006;47:199A-200A.
3. Husted S, Harrington RA, Cannon CP, Storey RF, Wickens M, Price D, Emanuelsson H. AZD6140, a reversible oral ADP receptor antagonist, does not increase risk of bleeding vs the thienopyridine clopidogrel in patients undergoing CABG surgery in the DISPERSE2 trial. *Am J Cardiol* 2006;S:521.
4. Storey RF, Harrington RA, Husted S, Heptinstall S, Wilcox RG, Gurbel PA, Grande P, Sanders N, Peters G, Emanuelsson H, Cannon CP. AZD6140 yields additional suppression of platelet aggregation in patients with acute coronary syndromes previously treated with clopidogrel. *J Am Coll Cardiol* 2006;47:204A.
5. Emanuelsson H, Mahaffey KW, Harrington RA, Husted S, Storey RF, Sanders N, Peters G, Cannon CP. Can greater inhibition of platelet aggregation be tolerated? Evaluation of the bleeding risk of AZD6140 compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS). *J Am Coll Cardiol* 2006;47:212A.
6. Husted S, Storey RF, Harrington RA, Sanders N, Peters G, Emanuelsson H, Cannon CP. The effects of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes (ACS). *J Am Coll Cardiol* 2006;47:200A.
7. [Storey RF](#), [Husted S](#), [Harrington RA](#), [Heptinstall S](#), [Wilcox RG](#), [Peters G](#), [Wickens M](#), [Emanuelsson H](#), [Gurbel P](#), [Grande P](#), [Cannon CP](#). Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. *J Am Coll Cardiol* 2007;50:1852-6.